focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOndine Biomed Regulatory News (OBI)

Share Price Information for Ondine Biomed (OBI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.75
Bid: 6.50
Ask: 7.00
Change: 0.00 (0.00%)
Spread: 0.50 (7.692%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 6.75
OBI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Ondine receives funding for meat photodisinfection

5 Dec 2022 07:00

RNS Number : 5216I
Ondine Biomedical Inc.
05 December 2022
 

Ondine Biomedical Inc.

("Ondine Biomedical", "Ondine" or the "Company")

Ondine receives funding for meat photodisinfection

· Funding of up to $735,000 towards development of prototype of novel photodisinfection application for use in food production.

· Up to 30% of food is lost due to degradation according to the UN.[1]

· Photodisinfection kills all types of pathogens - viruses, bacteria, and fungi - without creating resistance.

Ondine Biomedical Inc. (LON:OBI): Canadian life sciences company, Ondine Biomedical, has received funding of nearly $735,000 from Agriculture and Agri-Food Canada (AAFC) towards development of a food-safe photodisinfection method for Canada's meat packing industry. Ondine will leverage its proven medical photodisinfection technology platform to create a novel, photodynamic disinfection process to destroy pathogens on meat products without causing microbial resistance.

The Canadian meat processing industry has an urgent need for the development of technologies to reduce the incidence of food-borne pathogens including bacteria, fungi, viruses, and protozoa. Eradicating these invasive microbes will help protect the $9.4 billion (2021) Canadian meat export industry, as well enhance as the lives and welfare of Canadian consumers by reducing the incidence of food-borne illnesses.

Pathogens, such as Staphylococcus aureus and MRSA, are known to spread easily in meat packing facilities, especially in the pork industry.[2] Reducing the spread of these deadly pathogens is critical not only for consumer safety but also for that of the employees and the livestock at these facilities. Photodisinfection is highly effective against these pathogens, with recent research showing that Ondine's technology eliminated more than 99.9% of S. aureus in only 60 seconds, irrespective of the pathogen's level of antibiotic resistance[3].

Dr. Nicolas Loebel, President and Chief Technology officer of Ondine Biomedical Inc. said:

"Approximately 3.5 billion kilograms of poultry and meat are wasted every year globally, with a significant portion of this due to microbial spoilage. The related costs of beef spoilage alone in Canada are estimated at $200 million per year. Our innovative, rapid, and inexpensive approach to broad-spectrum disinfection has been proven both safe and effective for over a decade in Canadian hospitals, allowing tens of thousands of patients to reduce their risk of an antibiotic-resistant surgical site infection. Recognizing the impact of antibiotic resistance in the meat packing industry, we realized that we could deploy the same technology in food safety - eliminating tough, food-borne pathogens which can undermine the health and safety of all Canadians. We are delighted to be recognized by Agriculture and Agri-Food Canada as a key contributor in their fight against this problem and believe we are uniquely positioned to develop an effective solution."

The Honourable Marie-Claude Bibeau, Minister of Agriculture and Agri-Food:

"Processors across the country are committed to providing safe and high-quality products to Canadians. Innovative technology helps processors achieve this standard, as it provides solutions to problems, increases productivity and maintains efficacy. The Government of Canada is committed to investing in projects that keep our food safe over the long-term."

The Honourable Hedy Fry PC Member of Parliament for Vancouver Centre, British Columbia:

"I commend Ondine for all it's accomplished, not only here in Vancouver, but on behalf of Canadians. The company is helping establish a reliable technology that can keep meat safe for consumers, now and in the future. Today's investment will help Ondine continue its work, provide guidance and support the agriculture sector's long-term growth."

The project announced today is funded in part by the Government of Canada under the Canadian Agricultural Partnership's AgriScience Program, a federal, provincial, territorial initiative. The AgriScience Program aims to accelerate the pace of innovation by providing funding and support for pre-commercial science activities and cutting-edge research that benefits the agriculture and agri-food sector and Canadians. The government is contributing an estimated 50 % of the project's overall costs.

###

Ondine Biomedical Inc.

 

Angelika Vance, Corporate Communications

+001 (1) 604 838 2702

 

 

Strand Hanson Limited (Nominated and Financial Adviser)

 

James Harris, James Dance, Richard Johnson

+44 (0) 20 7409 3494

 

 

RBC Capital Markets

 

Rupert Walford, Kathryn Deegan

+44 (0) 20 7653 4000

 

Singer Capital Markets

 

Aubrey Powell, Asha Chotai

+44 (0)20 7496 3000

Vane Percy & Roberts (Media Contact)

Simon Vane Percy, Amanda Bernard

+44 (0) 77 1000 5910

 

Microbial foodborne disease

Foodborne illnesses are a major public health concern due to the high risk of microbial contamination of food. In 2010, more than 580 million illnesses and 351,000 deaths worldwide were associated with food contaminated by enteric pathogens according to a World Health Organization (WHO) estimate. Meat and meat-based products are particularly prone to contamination, accounting for more than 16% of total foodborne outbreaks in Europe in 2016.

Source: Int. J. Environ. Res. Public Health 2020, 17, 688; doi:10.3390/ijerph17030688

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. In addition to nasal photodisinfection (Ondine's lead product), products include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, wounds, and other indications related to healthcare associated infections.

 


[1] https://www.fao.org/in-action/seeking-end-to-loss-and-waste-of-food-along-production-chain/en/

[2] https://oem.bmj.com/content/78/7/530

[3] https://ondinebio.com/wp-content/uploads/2022/10/IPS-2022-Poster-Ondine-aPDT-against-clinical-isolates-of-MRSA-FINAL.pdf

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAMZMGZMDZGZZZ
Date   Source Headline
13th May 20249:30 amRNSNOTIFICATION OF MAJOR HOLDINGS
10th May 20247:00 amRNSECDC report shows rising HAIs and antibiotic use
8th May 20247:00 amRNSFurther Result of Fundraising
3rd May 20244:27 pmRNSResult of Fundraising
3rd May 20248:00 amRNSOndine announces proposed fundraising
2nd May 20246:25 pmRNSRelated Party Transactions
25th Apr 20247:00 amRNSNew study confirms nose is key source of infection
24th Apr 20247:00 amRNSCorporate and Trading Update
22nd Apr 20247:00 amRNSSteriwave in first Australian hospital
15th Apr 20247:00 amRNS32% Fewer SSIs After Steriwave Replaced Mupirocin
10th Apr 20247:00 amRNSSteriwave authorized for use by HCA UK
4th Apr 20247:00 amRNSEntry into ICU market expands revenue potential
28th Mar 202412:52 pmRNSAppointment of Interim Chief Financial Officer
25th Mar 20247:00 amRNSFirst commercial adoption of Steriwave by the NHS
21st Mar 20247:00 amRNSSteriwave study shows 77% drop in antibiotic use
15th Mar 20245:10 pmRNSReplacement: Steriwave deploying in 8 new sites
15th Mar 20247:00 amRNSSteriwave deploying in eight new sites
5th Mar 20249:45 amRNSOndine starts first UK health economics study
31st Jan 20247:00 amRNSMicrobiome research supports use of Steriwave
26th Jan 20247:00 amRNSOndine unveils new research at SPIE Photonics West
26th Jan 20247:00 amRNSGrant of Share Options
16th Jan 20248:15 amRNSAppointment of new Chief Financial Officer
13th Dec 20237:00 amRNSC$4.91 raise supports ongoing commercialisation
12th Dec 20231:20 pmRNSTR-1: NOTIFICATION OF MAJOR HOLDINGS
11th Dec 20236:15 pmRNSResult of Fundraising
5th Dec 20237:00 amRNSResult of Placing & Broker Option Update
4th Dec 20231:28 pmRNSClose of Bookbuild
1st Dec 20236:13 pmRNSUpdate. Re investor-led financing
30th Nov 20236:40 pmRNSOndine announces investor-led financing
16th Nov 20237:00 amRNSPhotodisinfection recommended as Standard of Care
31st Oct 20239:00 amRNSSteriwave use expanded following successful pilot
23rd Oct 20237:00 amRNS66.5% reduction in spine surgery infection rate
18th Oct 20237:00 amRNSSteriwave shown to reduce resistant bacteria
13th Oct 20237:00 amRNSSteriwave now in Canada's East Coast
10th Oct 20239:00 amRNSOndine to present poster at IP2023, Liverpool
9th Oct 20237:00 amRNSHospital to adopt Steriwave as standard-of-care
29th Sep 20239:00 amRNSBurnaby Hospital deploys Steriwave
25th Sep 20239:00 amRNSHalf-year Report
21st Sep 20237:00 amRNSMontreal Heart Institute pilots Steriwave
14th Sep 202312:00 pmRNSSteriwave proven effective against XDR bacteria
12th Sep 20239:00 amRNSSteriwave evaluation at major heart institute
30th Aug 20237:00 amRNSNotice of Results and Investor Presentation
29th Aug 20239:30 amRNSOndine to present new AMR research at ICPIC Geneva
21st Aug 20237:00 amRNSIssue of Equity and TVR
7th Aug 20239:00 amRNSOndine technology used in major Canadian hospital
1st Aug 20237:00 amRNSOndine commences first NHS Steriwave® pilot
17th Jul 202310:04 amRNSOndine receives impact award at IPA World Congress
7th Jul 20235:58 pmRNSCorporate Update
22nd Jun 20239:00 amRNSPhotodisinfection cuts COVID in meat processing
25th May 20237:00 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.